"We do await further progression-free survival data, but the early look looks quite interesting," concluded Dr. Bendell. "Also, we are very interested in the biomarker data that will be associated with this looking at whether or not – like we see in non–small cell lung cancer – if over–Met expression has some sort of effect on how patients do with colorectal cancer."
Amgen sponsored the trial. Dr. Van Cutsem reported receiving research funding from Amgen. Dr. Bendell reported having no relevant conflicts of interest.